Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

On May 6, we retained Becton, Dickinson and Company (BDX - Analyst Report) at Neutral based on the performance of the company in fiscal second quarter 2013.

Why the Retention?

On May 2, Becton Dickinson announced results for the reported quarter. The company reported adjusted earnings per share from continuing operations of $1.44, beating the Zacks Consensus Estimate of $1.35 per share.

Becton Dickinson recorded second-quarter revenues of $2,000.4 million, up 3.7% (up 4.1% in constant currency) year over year, sailing past the Zacks Consensus Estimate of $1,986 million.

On a geographic basis, domestic revenues (contributing 41.2% in the second quarter) inched up 0.3% year over year to $823.6 million while overseas revenues increased 6.2% (up 6.9% in constant currency) to $1,176.8 million.

Domestic revenues were negatively affected by the timing of orders while international revenues were boosted by growth in the emerging nations and robust growth of safety engineered products. Revenues from emerging markets accounted for about 23% of sales in the second quarter of fiscal 2013 (growing at 13% in constant currency year over year).

In March 2013, Becton Dickinson took over Cato Software Solutions, a provider of composite medicinal safety offerings for pharmaceutical medical preparations. Cato lays out an automated system to cut down medication mistakes.   

Following the release of the fiscal second quarter results, the Zacks Consensus Estimate for fiscal 2013 has inched up (over the last 7 days) by 2 cents to $5.73. The Zacks Consensus Estimate for fiscal 2014 has remained stagnant at $6.23 during the same timeframe.

Med-Tech Stocks That Warrant a Look

The stock carries a Zacks Rank #3 (Hold). Accuray Incorporated (ARAY - Analyst Report), Heartware International Inc. (HTWR - Snapshot Report) and Intuitive Surgical, Inc. (ISRG - Analyst Report) each carry a Zacks Rank #2 (Buy) and are expected to do well.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%